ADVERTISEMENT
ADVERTISEMENT

Anti-Inflammatory Research

Karen Young Kreeger's article entitled "New Molecular Targets Reviving Anti-Inflammatory Therapeutics" in the July 7, 1997, issue of The Scientist (page 1) overlooked an important company that is devoted exclusively to research on selective anti-inflammatory agents. LeukoSite Inc., founded in 1993 and located in Cambridge Mass., is developing and commercializing novel therapeutics for the treatment of inflammatory and autoimmune diseases. Using an approach that focuses on identifying the speci

Bruce Ganem

Karen Young Kreeger's article entitled "New Molecular Targets Reviving Anti-Inflammatory Therapeutics" in the July 7, 1997, issue of The Scientist (page 1) overlooked an important company that is devoted exclusively to research on selective anti-inflammatory agents.

LeukoSite Inc., founded in 1993 and located in Cambridge Mass., is developing and commercializing novel therapeutics for the treatment of inflammatory and autoimmune diseases. Using an approach that focuses on identifying the specific signaling involved in leukocyte recruitment and chemotaxis, the company has identified therapeutic targets in ischemic tissue injury, organ transplant, inflammatory bowel disease, atherosclerosis, rheumatoid arthritis, asthma, and AIDS.

The list of corporate Web sites in the article should also have included LeukoSite's: http://www.leukosite.com/.

Bruce Ganem
Member, Scientific Advisory Board LeukoSite Inc.
Franz and Elisabeth Roessler Professor
Department of Chemistry
Baker Laboratory
Cornell University
Ithaca, N.Y. 14853-1301
E-mail bg18@cornell.edu

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT